PAA
CYTK icon

Peregrine Asset Advisers’s Cytokinetics CYTK Stock Holding History

Peregrine Asset Advisers’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-45,779
Closed -$530K – 154
2013
Q2 		$530K Buy
+45,779
New +$361K 0.55% 43

Other funds holding CYTK

LPLP
Lansdowne Partners Limited Partnership London, United Kingdom $11.9B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
IIM
Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return

Peregrine Asset Advisers's CYTK Position: Q3 2013 in Review

Peregrine Asset Advisers sold out of Cytokinetics (CYTK) in Q3 2013, closing a stake of 45,779 shares — an estimated $530K sold.

Peregrine Asset Advisers first reported a position in CYTK in Q2 2013 and held it in 1 quarter. The position peaked at $530K in Q2 2013. 101 funds tracked by Wall St. Rank hold CYTK as of Q3 2013.

  • Peregrine Asset Advisers reported no remaining Cytokinetics position as of Q3 2013 after selling out during the quarter.
  • Peregrine Asset Advisers sold 45,779 Cytokinetics shares in Q3 2013, an estimated $530K.
  • Peregrine Asset Advisers first reported a position in Cytokinetics in Q2 2013 and held it in 1 quarter.
  • Peregrine Asset Advisers's Cytokinetics position peaked at $530K in Q2 2013.
  • 101 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2013.

Based on Peregrine Asset Advisers's 13F filing for Q3 2013, filed 14 Nov 2013.